Skip to main content

Table 3 Baseline characteristics in matched pairs of patients with NPC

From: Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients

Patient characteristic

Group 1 ( N = 270 pairs)

Group 2 ( N = 34 pairs)

Group 3 ( N = 379 pairs)

Group 4 ( N = 60 pairs)

RT [ n (%)]

CRT [ n (%)]

RT [ n (%)]

CRT [ n (%)]

RT [ n (%)]

CRT [ n (%)]

RT [ n (%)]

CRT [ n (%)]

Age (years)

        

≤45

138 (51.1)

138 (51.1)

18 (52.9)

18 (52.9)

171 (45.1)

171 (45.1)

31 (51.7)

31 (51.7)

>45

132 (48.9)

132 (48.9)

16 (47.1)

16 (47.1)

208 (54.9)

208 (54.9)

29 (48.3)

29 (48.3)

Sex

        

Male

71 (26.3)

71 (26.3)

8 (23.5)

8 (23.5)

79 (20.8)

79 (20.8)

15 (25.0)

15 (25.0)

Female

199 (73.7)

199 (73.7)

26 (76.5)

26 (76.5)

300 (79.2)

300 (79.2)

45 (75.0)

45 (75.0)

TNM classification

        

I

4 (1.5)

4 (1.5)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

II

266 (98.5)

266 (98.5)

34(100.0)

34 (100.0)

0 (0)

0 (0)

0 (0)

0 (0)

III

0 (0)

0 (0)

0 (0)

0 (0)

293 (77.3)

293 (77.3)

39 (65.0)

39 (65.0)

IV

0 (0)

0 (0)

0 (0)

0 (0)

86 (22.7)

86 (22.7)

21 (35.0)

21 (35.0)

T category

        

T1

72 (26.7)

72 (26.7)

9 (26.5)

9 (26.5)

38 (10.0)

38 (10.0)

3 (5.0)

3 (5.0)

T2

198 (73.3)

198 (73.3)

25 (73.5)

25 (73.5)

92 (24.3)

92 (24.3)

12 (20.0)

12 (20.0)

T3

0 (0)

0 (0)

0 (0)

0 (0)

167 (44.1)

167 (44.1)

24 (40.0)

24 (40.0)

T4

0 (0)

0 (0)

0 (0)

0 (0)

82 (21.6)

82 (21.6)

21 (35.0)

21 (35.0)

N category

        

N0

28 (10.4)

28 (10.4)

3 (8.8)

3 (8.8)

87 (23.0)

87 (23.0)

10 (16.7)

10 (16.7)

N1

242 (89.6)

242 (89.6)

31 (91.2)

31 (91.2)

103 (27.2)

103 (27.2)

20 (33.3)

20 (33.3)

N2

0 (0)

0 (0)

0 (0)

0 (0)

185 (48.8)

185 (48.8)

30 (50.0)

30 (50.0)

N3

0 (0)

0 (0)

0 (0)

0 (0)

4 (1.1)

4 (1.1)

0 (0)

0 (0)

  1. CRT, chemoradiotherapy; RT, radiotherapy. Group 1: early-stage disease with platelet count ≤300 × 109/L; Group 2: early-stage disease with platelet count >300 × 109/L; Group 3: locoregionally advanced disease with platelet count ≤300 × 109/L; Group 4: locoregionally advanced disease with platelet count >300 × 109/L.